Furthermore, in NSCLC, Celecoxib promotes ATF4 expression by upregulating Inc-HFE2-2:1, thereby activating the ER stress to enhance tumor cell apoptosis (27). The gene discussed is ATF4; the disease is non-small cell lung carcinoma.